Whether your rhinitis is seasonal (pollen-triggered) or year-round (house dust mite, pet dander), this guide addresses the practical coverage and access questions.
Does My Medical Aid Have to Cover This?
Partially. Allergic rhinitis is not a CDL condition. There is no PMB statutory minimum treatment benefit for routine rhinitis management. Medications are funded from the MSA (or ATB if applicable). Specialist consultations with an allergist or ENT surgeon are covered through the specialist consultation benefit.
If allergic rhinitis is your primary condition and it is well-managed on simple medications, the annual cost is typically within the MSA without creating financial pressure.
Getting the Right Diagnosis
A confirmed allergen-specific diagnosis is the foundation of optimal rhinitis management. Skin prick testing (SPT) or specific IgE blood tests (RAST) identify the causative allergen(s) — this informs avoidance measures and, if immunotherapy is considered, the allergen to include in the desensitisation formulation.
Both SPT and RAST are diagnostic tests covered under the diagnostic investigation benefit. SPT is performed in an allergist's rooms (intradermal pricks with standardised allergen extracts) and read at 15 minutes. RAST is a blood test processed by a laboratory. Confirm with your scheme whether these are covered under the specialist consultation benefit or the diagnostic investigation benefit — they may be billed differently.
First-Line Treatment: What Works and What It Costs
For most patients, the following combination is highly effective and inexpensive:
Intranasal corticosteroid spray (daily): The single most effective treatment for nasal symptoms, particularly congestion. Fluticasone (Flixonase), mometasone (Nasonex), or budesonide (Rhinocort). Once-daily use. Monthly cost: R150–R250 on prescription. These must be used consistently, not just during acute episodes.
Oral antihistamine (as needed or daily): Cetirizine, loratadine, or fexofenadine. Effective for sneezing, itch, runny nose. Most are OTC — your plan may not fund OTC medications, so check whether a prescription version is available on your formulary.
Saline nasal rinses: Inexpensive and effective as an adjunct; removes allergens and thins secretions. Can be performed with a neti pot or commercial saline sachet system. R100–R200/month. Self-funded; not prescription-dependent.
This combination manages mild-to-moderate allergic rhinitis in the majority of patients at very low annual cost.
When to See an Allergist
See a clinical allergist or ENT surgeon if: - Symptoms persist despite adequate first-line treatment - You want to identify the specific causative allergen for avoidance or immunotherapy - You are considering allergen-specific immunotherapy - Nasal polyps are suspected (change in sense of smell, unilateral nasal blockage) - Symptoms are significantly affecting work, school, sleep, or quality of life
An allergist consultation is covered through the specialist benefit. Confirm your plan's approved rate for allergist consultations and whether a GP referral letter is required.
Allergen Immunotherapy: What to Know Before Starting
Subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) is a 3–5 year treatment course. It is the only treatment that modifies the underlying allergic disease rather than suppressing symptoms. Before committing to immunotherapy, confirm:
Coverage: Contact your scheme and ask specifically: "Does the plan have a benefit for allergen-specific immunotherapy (SCIT or SLIT) and, if so, what is covered and is exceptional-needs authorisation required?" Get the answer in writing before starting.
Commitment: SCIT requires regular clinic visits (weekly to monthly) for 3–5 years. SLIT is daily home administration for the same duration. Both require sustained commitment; partially completed immunotherapy courses are less effective.
Allergy assessment first: Immunotherapy targets specific allergens — you must know which allergen(s) you are allergic to before the allergen formulation can be prepared. Allergen testing is the first step.
If the scheme has no immunotherapy benefit, discuss with your allergist whether SLIT (lower cost than SCIT; self-administered at home) is an option that fits within a self-funded budget, given its long-term disease-modifying value.
Montelukast: The Neuropsychiatric Warning
Montelukast (Singulair) has a black box warning from SAHPRA / FDA for neuropsychiatric effects including mood changes, agitation, anxiety, nightmares, suicidal ideation, and completed suicide in rare cases. These effects have been reported in children and adults. When prescribed for rhinitis (as opposed to asthma, where it may be more specifically indicated), ensure you and your prescriber have discussed this risk. Report any mood or behaviour changes to your doctor immediately.
House Dust Mite Avoidance: The Single Most Impactful Environmental Measure
For perennial rhinitis driven by house dust mite (the most common SA allergen), allergen-proof mattress and pillow covers are the most evidence-based environmental intervention. Cost: R500–R1,500 once-off. Regular hot washing of bed linen (>60°C kills HDM). These measures can meaningfully reduce allergen load and improve symptom control — independent of any medical treatment.
Checklist
| Action | Priority |
|---|---|
| Start intranasal corticosteroid spray if not already using | Immediately |
| Get allergen testing (SPT or RAST) if causative allergen unknown | At allergist |
| Confirm immunotherapy benefit with scheme before starting | Before committing |
| Check montelukast neuropsychiatric warning if prescribed | This week |
| Implement HDM avoidance measures if HDM confirmed | This week |
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Eye Symptoms: Allergic Conjunctivitis
Allergic rhinitis and allergic conjunctivitis (itchy, red, watery eyes) frequently co-exist — they share the same IgE-mediated mechanism and are often triggered by the same allergen. If you have both nasal and eye symptoms, treatment addresses both simultaneously.
Intranasal corticosteroids reduce nasal symptoms but have limited effect on eye symptoms. Oral antihistamines help with both. Topical antihistamine or mast cell stabiliser eye drops (sodium cromoglycate, olopatadine, ketotifen) are highly effective for eye symptoms and are available at pharmacies. Monthly cost: R100–R250.
If eye symptoms are severe (significant chemosis, photophobia, periorbital oedema) or persistent despite standard antihistamine therapy, an ophthalmologist or allergy specialist review is warranted. Confirm with your scheme whether topical eye drops are fundable on prescription — they are often available OTC but a prescription enables benefit funding.
Co-existing Asthma: The One Airway Concept
If you have both allergic rhinitis and asthma, treating one condition well improves the other. Intranasal corticosteroid use in asthma patients with rhinitis has been shown to reduce asthma-related emergency visits. Montelukast is particularly useful when both conditions co-exist as it addresses both nasal and bronchial inflammation through the leukotriene pathway.
Ensure your AURA profile includes both conditions — optimal plan selection for the dual-condition profile may differ from single-condition rhinitis.